Nyxoah SA

Stage 4 · Declining · week 60

As of Oct 22, 2026, Nyxoah SA is in Stage 4, the downtrend phase, now in week 60 (since Aug 19, 2025). It closed at $0.82, 86.0% below its 52-week high and below its 200-day average, which is falling.

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. More about the company

$0.82

-8.16% today

$83.7M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is NYXH early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 61w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 2w → S3 8w → S4 13w → S1 3w → S2 10w → S3 10w → S4 12w → S1 10w → S4 7w → S1 1w → S2 9w → S3 2w → S4 9w → S1 7w → S4 61w current

Total tracked: 165 weeks across 15 stage runs.

NYXH among Medical Devices116th of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…116	NYXHNyxoah SA	Stage 4 · wk 60	9	−38.2%

vs 52W High

-86.0%

$0.82 lo$5.89 hi

86.0% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 60

1w13w26w

Week 60, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-68.7%

200 DMA: $2.63 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.95x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-38.2%

-41.3%

-73.1%

YTD

-81.7%

-85.7%

Scan Membership

Breakout Watch

Latest: 2025-01-31

4 appearances in last 60 days. First seen: 2023-04-27.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 60 · Vol 1.95x

2026-10-21S4

Wk 60 · Vol 1.26x

2026-10-20S4

Wk 59 · Vol 1.48x

2026-10-19S4

Wk 59 · Vol 1.57x

2026-10-16S4

Wk 59 · Vol 0.68x

2026-10-15S4

Wk 59 · Vol 0.43x

2026-10-14S4

Wk 59 · Vol 0.29x

2026-10-13S4

Wk 58 · Vol 0.19x

2026-10-12S4

Wk 58 · Vol 0.46x

2026-10-09S4

Wk 58 · Vol 0.11x

2026-10-08S4

Wk 58 · Vol 0.28x

2026-10-07S4

Wk 58 · Vol 0.26x

Moving averages & range

50 DMA

$1.43

200 DMA

$2.63

52W High

$5.89

52W Low

$0.82

5D Low

$0.82

Resistance levels (recent highs)

20d High

$1.59

60d High

$1.76

120d High

$3.33

250d High

$5.89

Next resistance

+93.4%

to 20d High

ROE

-122.7%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.9

Nyxoah SA: quick answers

What stage is Nyxoah SA in?

As of Oct 22, 2026, Nyxoah SA (NYXH) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 19, 2025 and is in week 60. What the four stages mean

Is Nyxoah SA in an uptrend?

No. Nyxoah SA is in a Stage 4 downtrend. It trades 68.7% below its 200-day average, which is falling.

How far is Nyxoah SA from its 52-week high?

Nyxoah SA closed at $0.82 on Oct 22, 2026, 86.0% below its 52-week high of $5.89. Its 52-week low is $0.82.

How has Nyxoah SA performed over the past year?

As of Oct 22, 2026, Nyxoah SA is down 85.7% over the past year and down 81.7% so far in 2026.

Which sector and industry is Nyxoah SA in?

Nyxoah SA is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.